Abstract:
Objective: To explore the expression of pituitary tumor transforming gene (PTTG), matrix metalloprotein -ase- 2 (MMP- 2) and vascular endothelial growth factor (VEGF) in ovarian serous tumor, and to investigate the function of PTTG in malignant transformation, invasiveness and metastasis of ovarian serous tumor. Methods:The expression of PTTG, MMP- 2 and VEGF was examined with immunohistochemistry in 30tissue samples of ovarian serous cystadenoma, 21 tissue samples of ovarian borderline serous cystadenoma and 30tissue samples of ovarian serous cystadenocarcino-ma including primary and metastatic sites. Results: There was a significant difference in the expression of PTTG among the three groups of ovarian serous tumor ( P<0.01). PTTG expression in ovarian borderline serous cystadenoma was higher than that in ovarian serous cystadenoma (P<0.01). The primary site of ovarian serous cystadenocarcinoma showed higher PTTG expression than ovarian borderline serous cystadenoma (P<0.01). Compared with the primary site, the metastatic site of ovarian serous cystadenocarcinoma showed higher PTTG expression (P<0.05). The expression of MMP-2 in ovari -an serous cystadenocarcinoma primary site and ovarian borderline serous cystadenoma was higher than in ovarian serous cystadenoma ( P<0.01). MMP- 2 expression in the ovarian serous cystadenocarcinoma metastatic site was higher than in pri-mary site ( P<0.05). VEGF expression in the ovarian serous cystadenocarcinoma primary site and ovarian borderline se -rous cystadenoma was higher than in ovarian serous cystadenoma ( P<0.05). No significant difference was found in VEGF expression between the primary site and metastatic site of ovarian serous cystadenocarcinoma ( P>0.05). The expression of PTTG was positively correlated with MMP- 2 and VEGF in ovarian serous tumor. Conclusion:The expression level of PTTG was correlated with the degree of malignancy and invasiveness. PTTG may participate the malignant transformation and may play an important role in the invasiveness and metastasis of ovarian serous tumor by up-regulating MMP-2 and VEGF expression.